Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million upfront, targeting ultra-rare epilepsy

Jazz Pharmaceuticals announced it will purchase Actio Biosciences, a company developing an ultra‑rare epilepsy therapy.

The transaction includes an upfront cash payment of $820 million, with the possibility of an additional $500 million tied to future milestones.

The acquisition expands Jazz’s portfolio in the neurological space and underscores its continued focus on epilepsy treatments.

No further details on the drug name or timeline were provided in the announcement.